**In silico derived** small molecules targeting the finger-finger interaction between the histone lysine methyltransferase NSD1 and Nizp1 repressor

Andrea Berardi *,1, Michela Ghitti 1, Giacomo Quilici, Giovanna Musco *

Biomolecular NMR Group, Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Via Olgettina 58, 20132 Milano, Italy

**A R T I C L E  I N F O**

Article history:
Received 10 September 2020
Received in revised form 23 November 2020
Accepted 23 November 2020
Available online 3 December 2020

Keywords:
PHD finger
NSD1
Nizp1
Protein-protein interactions
Virtual screening
NMR

**A B S T R A C T**

PHD fingers are small chromatin binding domains, that alone or in tandem work as versatile interaction platforms for diversified activities, ranging from the decoding of the modification status of histone tails to the specific recognition of non-histone proteins. They play a crucial role in their host protein as mutations thereof cause several human malignancies. Thus, PHD fingers are starting to be considered as valuable pharmacological targets. While inhibitors or chemical probes of the histone binding activity of PHD fingers are emerging, their druggability as non-histone interaction platform is still unexplored. In the current study, using a computational and experimental pipeline, we provide proof of concept that the tandem PHD finger of Nuclear receptor-binding SET (Su(var)3–9, Enhancer of zeste, Trithorax) domain protein 1 (PHD₃₋₅(CH₃₄0₋₅)) is ligandable. Combining virtual screening of a small subset of the ZINC database (Zinc Drug Database, ZDD, 2924 molecules) to NMR binding assays and ITC measurements, we have identified Mitoxantrone dihydrochloride, Quinacrine dihydrochloride and Chloroquine diphosphate as the first molecules able to bind to PHD₃₋₅(CH₃₄0₋₅) and to reduce its documented interaction with the Zinc finger domain (C2HR₄₋₅) of the transcriptional repressor Nizp1 (NSD1-interacting Zn-finger protein). These results pave the way for the design of small molecules with improved effectiveness in inhibiting this finger-finger interaction.

© 2020 The Author(s). Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

PHD fingers are small and abundant non-catalytic Zn²⁺ binding domains annotated in more than 170 human chromatin-related proteins [1]. They are often present in single or multiple copies or in tandem with other epigenetic reader domains in so called erasers or writers, i.e. enzymes harboring catalytic domains able to change the chromatin modification status [2–4]. They are typically involved in the recognition of specific histone marks (H3K4me0, H3K4me3, H3K9me3) to modulate the transcriptional activity of the hosting protein [5,6]. Mutations of PHD fingers can lead to aberrant protein functions that on turn can trigger different pathological conditions, including neurological and developmental diseases, cancer and immunological disorders [7]. Hence, similarly to other chromatin binding domains such as BRD [8] and PWWP [9], PHD fingers are becoming appealing epigenetic drug targets, thus representing a promising pharmacological alternative to classical enzymatic inhibition strategies of their host protein [10–14]. Importantly, the versatile structural scaffold of PHD fingers, alone or in tandem with other chromatin binding domains, results in diversified functions that go beyond the perceiving of the epigenetic landscape [15]. In particular, they have emerged as multifaceted interaction platforms, well-suited for bridging their host proteins with other subunits of bigger macromolecular chromatin complexes [12,16,17], herewith offering additional pharmacological intervention opportunities. A paradigmatic example of PHD fingers serving as hub for protein–protein interactions is represented by the tandem PHD finger of Nuclear receptor-binding SET (Su(var)3–9, Enhancer of zeste, Trithorax) domain protein 1 (PHD₃₋₅(CH₃₄0₋₅)). Fifth PHD and C2HCH tandem domain of NSD1; C2HR₄₋₅, C2HR finger domain of Nizp1; NMR, Nuclear Magnetic Resonance; VS, Virtual Screening; STD, saturation transfer difference.

* Corresponding author.

E-mail addresses: berardi.andrea@hsr.it (A. Berardi), musco.giovanna@hsr.it (G. Musco).

1 These authors contributed equally to the work.

**Abbreviations:** PHD finger, Plant Homeodomain finger; NSD1, Nuclear receptor-binding SET (Su(var)3–9, Enhancer of zeste, Trithorax) domain protein 1; Nizp1, (NSD1-interacting Zn-finger protein); PHD₃₋₅(CH₃₄0₋₅), Fifth PHD and C2HCH tandem domain of NSD1; C2HR₄₋₅, C2HR finger domain of Nizp1; NMR, Nuclear Magnetic Resonance; VS, Virtual Screening; STD, saturation transfer difference.

https://doi.org/10.1016/j.csbj.2020.11.044
2001-0370© 2020 The Author(s). Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
acute myeloid leukemia (AML) [19] and to the inherited over-growth disease Sotos Syndrome [20]. Herein PHD/C5HCHNSD1 appears to play a pathophysiological role, as it contributes to oncogenesis and inappropriate Hox genes activation in AML condition [19] and is hotspot for Sotos Syndrome point mutations [18]. Moreover, it mediates the recruitment of its host protein to the repressive complex is still elusive, therefore the identification of chemical probes able to interfere with the PHD/C5HCHNSD1/C2HRNizp1 interaction would be a desirable tool to dissect its biological outcomes. Modulators of this finger-finger interaction might create new opportunities for the development of inhibitors of aberrant NSD1 function(s) and complement the classical block-ade of its histone methyl transferase activity [23]. In this framework we have previously solved the NMR structure of PHD/C5HCHNSD1, and shown that it does not recognize Histone H3 tail peptides, but it binds to C2HRNizp1. We have generated a three-dimensional model of the complex and shown that the interaction (Kd = 4 μM) is highly specific. In particular, an exposed evolutionary conserved RWR loop of C2HRNizp1 accommodates into the PHD/C5HCHNSD1 interdomain groove and creates hydrophobic and electrostatic intermolecular interactions [18], we allowed rotation of its hydroxyl group. LigPrep calculation was performed on the final 172 compounds with Prime [31,32] at 7 ± 2.0 pH units using standard parameters. Virtual screening was carried out in three steps including high-throughput virtual screening (HTVS), Standard Precision (SP), and extra precision (XP) docking stage, after each step, the best 30, 50 and 20% compounds in terms of docking score were kept, respectively. To obtain a post-processing ligand binding energy a molecular mechanics generalized Born surface area (MM-GBSA) calculation was performed on the final 172 compounds with Prime [33]. The best 50 molecules in terms of ΔG of binding were selected for visual inspection. Among them 19 unique compounds, commercially available and showing good solubility in water were selected for visual inspection. Among them 19 unique compounds, commercially available and showing good solubility in water were purchased for experimental validation. ADME-related properties of the selected compounds were evaluated using QikProp [30] program running in normal mode. QikProp generates physically relevant descriptors, and uses them to perform ADME predictions, number of violations of Lipinski’s rule of five [34] and of Jorgensen’s rule of three [35].

2.3. Reagents

The following molecules were purchased from Sigma-Merck: ZINC08101116 (Gentamicine sulfate), ZINC03872123 (Clozapine), ZINC00001547 (Hydroxystilbamidine bis(methanesulfonate)), ZINC08214681 (Streptomycin), ZINC08214483 (Amikacin), ZINC08214692 (Tobramycin), ZINC04213094 (Isoetemite), ZINC18098320 (Chlorhexidine), ZINC15030861 (Chloroquine diphosphate), ZINC00601274 (Astemizole), ZINC03830246 (Quina-crine dihydrochloride), ZINC03794794 (Mitoxantrone dihydrochloride), ZINC08214590 (Kanamycin). The following

2. Materials and methods

2.1. FTMap analysis

Hot spots identification was performed using the FTMap computational map server (www.ftmap.bu.edu). The lowest energy structure of PHD/C5HCHNSD1, as determined by NMR (PDB code PDB 2NAA) was uploaded into the FTMap server and ran according to instructions [26]. The results were visually inspected using PyMol [27].

2.2. Virtual screening

The in silico screening of the ZINC Drug Database (ZDD) against PHD/C5HCHNSD1 was performed using the virtual screening workflow of the Schrödinger software suite 2019-3 (Schrödinger, LLC, New York, NY, 2019). The lowest energy structure of PHD/C5HCHNSD1 (PDB 2NAA) [18] used for virtual screening was prepared with the Protein Preparation Wizard tool of Maestro [28]. The orientation of the solvent exposed hydroxyl groups of Serine, Threonine and Tyrosine were optimized. A restrained minimization was run using the OPLS force field [29] with a root mean square deviation (RMSD) tolerance on heavy atoms of 0.3 Å. The receptor grid was generated defining the centroid of active site residues E2204 and S2123, which are directly involved in PHD/C5HCHNSD1/C2HRNizp1 interaction [18] with a box dimension of 12 Å × 15 Å × 18 Å. As S2123 plays a fundamental role in complex formation [18], we allowed rotation of its hydroxyl group. LigPrep was used to prepare the 2924 compounds of the ZDD with Epik at 7 ± 2.0 pH units using standard parameters. Virtual screening was carried out in three steps including high-throughput virtual screening (HTVS), Standard Precision (SP), and extra precision (XP) docking stage, after each step, the best 30, 50 and 20% compounds in terms of docking score were kept, respectively. To obtain a post-processing ligand binding energy a molecular mechanics generalized Born surface area (MM-GBSA) calculation was performed on the final 172 compounds with Prime. The best 50 molecules in terms of ΔG of binding were selected for visual inspection. Among them 19 unique compounds, commercially available and showing good solubility in water were purchased for experimental validation. ADME-related properties of the selected compounds were evaluated using QikProp program running in normal mode. QikProp generates physically relevant descriptors, and uses them to perform ADME predictions, number of violations of Lipinski’s rule of five and of Jorgensen’s rule of three.

Fig. 1. Schematic representation of NSD1 and Nizp1 domain architecture and of the interaction between PHD/C5HCHNSD1 and C2HRNizp1. C-terminal residue numbers of NSD1 and Nizp1 domain boundaries of PHD/C5HCHNSD1 and C2HRNizp1 are indicated. The representation is not drawn to scale.
molecules were purchased from Mcule ZINC22443609 (plerixafor), ZINC3830583 (Clindamycin hydrochloride), ZINC52981502 (Netilmicin), ZINC03830924 (Idabucin HCl), ZINC04097283 (Lyncomycin hydrochloride), ZINC3830583 (Clindamycin hydrochloride), ZINC52981502 (Netilmicin), ZINC03830924 (Idabucin HCl), ZINC04097283 (Lyncomycin hydrochloride) and ZINC14880004 (Rolitetracycline).

2.4. Sample preparation for NMR and binding assays

Murine PHDvC5HCHNSD1 (Glu2117–Asp2207, NCBI Reference Sequence: NM 008739.3) and murine C2HR Nizp1 (residues Glu397–Lys434, corresponding to Glu398–Lys435 in the human sequence, NCBI Reference Sequence: NM 032752.3) were expressed in E. coli and purified as described in [18]. As the mouse PHDvC5HCHNSD1 sequence shares 99% identity with the human one (residues Glu2116–Asp2206 in the human sequence NM 022455.4), we adopted the human sequence numbering scheme for indirect dimension. Assignment of the labelled proteins in the presence of the ligands was obtained following individual perturbation (CSP) was calculated as CSP = [(ΔδHN + ΔδN/25)/2]1/2 [37].

Ligand titrations have been performed on 15N-PHDvC5HCHNSD1 adding 0.5, 1, 2, 3, 6, 10, 20 equivalents of ligands to the labelled protein. In order to minimize dilution and NMR signal loss, titrations were carried out by adding small aliquots of concentrated ligands (typically 10 mM, dissolved in 20 mM phosphate buffer, pH 6.3, 0.15 M NaCl) to the 15N labelled protein samples (0.13 mM, dissolved in NMR buffer).

Dissociation constant estimation. The apparent dissociation constants of the ligands–15N- PHDvC5HCHNSD1 interactions were estimated from least-squares fitting of CSPs as a function of total ligand concentration according to the following equation:

$$
\delta = \frac{b + v/2 - 4ac}{2a}
$$

with $a = 8(K_a/b_0)(|P|_o)$, $b = 1 + K_a([L]_i + [P]_i)$, and $c = b_0K_a([L]_i)[|P|_o]$ is the total ligand concentration at each titration point, $[P]_i$ is the total protein concentration, $K_a = 1/K_{d}$ is the association constant, and $b_0$ is the chemical shift of the resonance in the complex, $\delta$ is the absolute change in chemical shift for each titration point. The $K_d$ were obtained from the average plus the standard deviation of the fitting values of 7 residues, whose resonances were well resolved in the HSQC spectra and had CSP > 0.55 ± s. $b_0$ and $b_0$ were used as fitting parameters using the Xmgrace program (http://plasma-gate.weizmann.ac.il/Grace/).

Saturation Transfer Difference (STD) experiments. STD experiments have been performed on 2 mM ligands in the presence of 0.1 mM PHDvC5HCHNSD1 in NMR buffer. STD experiments were acquired using a pulse scheme (Bruker pulse sequence: stddiffesgp.3) with excitation sculpting with gradients for water suppression and spin-lock field to suppress protein signals. The spectra were acquired using 128 scans, a spectral width of 9600 Hz. 64 K data points for acquisition. For protein saturation, a train of 60 Gaussian shaped pulses of 50 ms was applied, for a total saturation times of 3 s, with relaxation delays of 3 s. On- and off-resonance irradiations were set at 0 ppm and at 107 ppm, respectively. STD spectra were obtained by internal subtraction of the on-resonance spectrum from the off-resonance spectrum. To analyze the STD effect we used the amplification factor (AF_{STD}) [38]. The AF_{STD} at a given ligand concentration ([L]_i) was obtained by multiplying the relative STD effect of a given ligand hydrogen (I_{STD}/I_o) to the peak integral in the STD spectrum and in the off-resonance spectrum, respectively, and $I_{STD} = I_oI_{SAT}$, where $I_{SAT}$ is the intensity of the saturated peak) with the molar ratio of ligand in excess relative to the protein ([L]_i/[P]):

$$
AF_{STD} = \frac{I_oI_{SAT}}{I_o} \times \frac{|[L]_i|}{|P|} = \frac{I_{STD}}{I_o} \times \frac{|[L]_i|}{|P|}.
$$

![Fig. 2. Ligandability assessment of PHDvC5HCHNSD1. A) Data driven docking model of PHDvC5HCHNSD1/C2HR Nizp1 complex [18]. PHDvC5HCHNSD1 and C2HR Nizp1 are represented in surface and cartoon, respectively. B) Fdmap consensus sites (CSs) identified on the PHDvC5HCHNSD1 structure. The protein and the CSs clusters, ranked from the highest to the lowest populated, are shown in solid and mesh surface, respectively.](attachment:image.png)
To obtain an epitope mapping we quantitatively expressed the differences in $A_{STD}$ for the different hydrogens calculating the relative STD effects ($STD\%$), whereby for each ligand the hydrogen with highest $A_{STD}$ was set to 100%, and used as a reference to calculate the relative STD effects for the other protons.

2.6. Isothermal titration calorimetry competition experiments

ITC titrations were performed at 23 °C using a VP-ITC isothermal titration calorimeter (MicroCal LLC, Northampton, MA, USA). Recombinant proteins and ligands were dissolved in the same buffer (20 mM NaH$_2$PO$_4$ /Na$_2$HPO$_4$ pH 7.2, 0.15 M NaCl, 2 mM betamercaptoethanol, 10 µM ZnCl$_2$). The $\Delta G$ of binding between C2HRNizp1 and PHD$_5$CSCH$_{NSD1}$ was previously determined in [18]. To monitor the inhibition activity of 1–3, we stepwise titrated 1.5–3 mM C2HRNizp1 into a cell containing a pre-formed protein–ligand complex (formed by 0.15 mM PHD$_5$CSCH$_{NSD1}$ with a 20-fold excess of either molecule 1, 2 or 3) up to a three or five-fold molar excess. The quantity of heat absorbed or released in the process was measured. Control experiments were performed under identical conditions to determine the dilution heat of the titrant C2HRNizp1 into buffer and of the buffer into protein–ligand samples. Data were analyzed with the software ORIGIN 7.0.

3. Results

3.1. Assessment of PHD$_5$CSCH$_{NSD1}$ ligandability

PPIs are traditionally classified as difficult pharmacological targets because of their 'poor druggability' reputation, mainly due to the structural and dynamic complexity of the interfacial features [24,39]. However, recent successful studies have challenged this assumption demonstrating that the targeting of protein–protein interfaces is feasible, thus increasing the possibilities of pharmacological interraces [40]. In particular, PPIs can be mediated by so-called "hot spots", where specific hydrophobic interactions and, to a lesser extent, polar interactions drive most of the affinity [41]. This is the case for PHD$_5$CSCH$_{NSD1}$/C2HRNizp1 interaction where hydrophobic and polar contacts formed by the R$_{A15}$W$_{R417}$ (RWR) loop of C2HRNizp1 and the PHD$_5$CSCH$_{NSD1}$ interdomain groove represent the major driving force for complex formation, as assessed by mutagenesis studies [18]. Prompted by these results, we applied FTMap [26] to assess in silico the ligandability of the surface of PHD$_5$CSCH$_{NSD1}$. Herein, the druggability of a target protein was defined based on two criteria: i) the number of probe clusters within a consensus site (CS) higher than 16 and ii) the existence of at least one additional weaker hot spot within 8 Å from the CS itself. FTMap identified 7 CSs (Fig. 2B), with the first two being the largest one that fulfilled the druggability requirements. In particular, the highest populated site (CS1) was composed by 20 probe clusters and was close to one weaker hot spot (CS7, consisting of 4 probes). The second one (CS2) contained 19 probes and was within 8 Å from two weaker hot spots (CS3, and CS4 consisting of 16 and 13 probes, respectively). Interestingly, CS2 was located at the interface between PHD$_5$CSCH$_{NSD1}$ and CSCH$_{NSD1}$, in the C2HRNizp1 interaction surface (Fig. 2), supporting the notion that this region could be druggable and appropriate for a virtual screening campaign.

3.2. Virtual screening: targeting the PHD$_5$CSCH$_{NSD1}$/C2HRNizp1 interaction surface

We used the Schrödinger Suite 2019-3 (Schrödinger Inc., LLC) to dock into PHD$_5$CSCH$_{NSD1}$ (pdb code: 2NAA) the ZINC Drug Database, composed by 2924 commercially available compounds, including worldwide commercially available approved drugs as pure compounds, Drugbank approved molecules and nutraceuticals, and Food and Drug Administration approved drugs. The screening workflow consisted in three sequential docking steps comprising a high-throughput virtual screening (HTVS), a Standard Precision (SP), and an extra precision (XP) docking stage. 172 compounds emerging from the XP step were subsequently re-ranked according to molecular mechanics generalized Born surface area (MM-GBSA) calculations (Fig. 3). The best 50 molecules in terms of binding energy were selected for visual inspection. Finally, 19 unique compounds, commercially available and showing good water solubility were selected for further experimental validation (Supplementary Table S1). The "drug-likeness", the bioavailability and the pharmacokinetic profiles of the candidates were assessed on the basis of Lipinski’s “Rule of Five” (Ro5) [34], Jorgensen’s “Rule of three” (Ro3) [35] and ADME properties (absorption, distribution, metabolism and excretion), respectively (Supplementary Table S1). As proposed by Jorgensen and Duffy [35] to assess the pharmacokinetic profiles of the selected compounds we used an overall ADME-compliance score (#stars), indicating the number of property descriptors computed by QikProp that fall outside the 95% range of similar values for known drugs. Herein, we observed that 21.1% and 26.3% of the compounds showed no Lipinski and Jorgensen violations, respectively, while the 85% and 100% showed ≤2 Ro5 and Ro3 violations, respectively (Supplementary Fig. S1). Moreover, the 79% of the selected candidates showed suitable ADME properties with up to a maximum of 5 molecular descriptors and predicted properties falling outside the normal range of known drugs, thus indicating that the selected molecules are expected to have good pharmacokinetic properties (Supplementary Fig. S2).

3.3. Hits validation

The water-soluble and commercially available hits identified in the virtual screening (19 molecules) (Table 1) were subsequently tested for their binding to PHD$_5$CSCH$_{NSD1}$ by NMR spectroscopy using protein-based methods [42] to assess possible interactions and mapping thereof on PHD$_5$CSCH$_{NSD1}$ structure. We stepwise titrated purified $^15$N-labeled PHD$_5$CSCH$_{NSD1}$ (0.13 mM) with increasing concentrations of ligand (up to 2.5 mM), whereby for each titration point we recorded heteronuclear single-quantum coherence (HSQC) spectra. 3 molecules turned out to be negative for binding, as judged by their $^15$N HSQC spectra that superimposed perfectly on a reference experiment (Supplementary Fig. S3A), and 7 molecules induced protein aggregation. 6 molecules caused very weak and scattered chemical shift perturbations (CSPs) on the protein surface, suggestive of aspecific interactions (Supplementary Fig. S4). Only 3 compounds (1, ZINC03794794 – Mitoxantrone dihydrochloride; 2, ZINC03830246 – Quinacrine dihydrochloride; 3, ZINC01530861 – Chloroquine dihydrophosphate) (Fig. 4A) proved to be positive, and induced several small but significant CSPs, indicative of weak interactions occurring in the fast exchange regime on the NMR time scale (Fig. 4B). By fitting the shifts of selected NMR peaks upon addition of increasing ligands concentrations we estimated a $K_d$ of 1.2 ± 0.4 mM for 1, 1.4 ± 0.3 mM for 2 and 4.7 ± 1.4 mM for 3 (Fig. 4C, Table 1). Overall, the pattern of significant CSPs (CSP > avg ± sd) was similar for the titrated molecules, with resonances of C2124NSD1, G2125NSD1, A2144NSD1, C2146NSD1 S2180NSD1, H2205NSD1 shifting upon addition of 1–3 (Fig. 5A, Supplementary Table S2). Here, projection onto the docking poses of the residues significantly shifting during ligands titrations allowed to generate a mapping of the interactions, which indicates that the three hits targeted one face of the inter-domain groove between PHDv and CSCH (Fig. 5B). Interestingly, the resonances of residues mostly affected by ligands binding coincided or were nearby those significantly affected by C2HRNizp1 interaction (Fig. 5C, Supplementary...
performed on a solution containing 2 mM ligand and 0.1 mM PHDvC5HCHNSD1 exhibited narrow and well resolved lines. Significant STD effects were observed for ligands 1–3 unequivocally demonstrating their binding to PHDvC5HCHNSD1 (Fig. 6A,B). To obtain group ligand epitopes [38], i.e. to identify those hydrogens in close contact with PHDvC5HCHNSD1, for each molecule we calculated the relative STD effect (STD%) at 2 s of saturation time. We observed that for the three molecules the aromatic protons displayed the highest relative STD effect (with 70–100% saturation), implying their close proximity to the protein. Conversely, the aliphatic protons contributed to a lesser extent suggesting only a modest involvement in the interaction (Fig. 6A,B). Overall, MM-GBSA refined docking poses of the three ligands were consistent with NMR chemical shift perturbations and in part with STD epitope mapping (Fig. 5, Fig. 7). Ligand Interaction Diagrams of the binding site showed that the aromatic moieties of all the compounds bound to the hydrophobic groove at the interface of PHDv and C5HCH establishing critical apolar interactions with residues L2147NSD1, C2178NSD1, P2179NSD1, F2182NSD1, E2204NSD1 and H2205NSD1 (Fig. 7A,B). In the docking poses all the compounds created also polar interactions with residues around the hydrophobic interface groove, whereby each compound established at least two hydrogen bonds with S2180NSD1 and the carbonyl of S2123NSD1. Molecule 1 and molecule 3 established additional polar contacts with E2120NSD1, C2112NSD1, C2178NSD1, H2205NSD1, and with the carbonyl of C2124NSD1, respectively (Fig. 7). However, the relatively low percentage of saturation in STD experiments observed for the methylene nearby the hydroxyl groups of molecule 1 and the N-ethyl groups of molecules 2 and 3 suggests that these aliphatic chains do not stably interact with PHDvC5HCHNSD1. Collectively, validation of the virtual screening hits through ligand based and protein based NMR experiments allowed to identify three aromatic ligands that specifically target the inter-domain region of PHDvC5HCHNSD1 that is recognized by the RWR motif of C2HRNizp1.

4. Molecules 1–3 reduce the interaction between C2HRNizp1 and PHDvC5HCHNSD1

As both the CSPs mapping of the interaction on PHDvC5HCHNSD1 and the docking poses suggested that 1–3 obstructed to a certain extent the C2HRNizp1 binding site (Fig. 1B, Fig. 7), we asked whether these molecules, despite their low binding affinity, were able to interfere at least in part in the interaction between PHDvC5HCHNSD1 and C2HRNizp1. To verify this hypothesis, we performed ITC experiments titrating C2HRNizp1 into PHDvC5HCHNSD1 solutions that were previously saturated with a twenty-fold excess of 1–3 and compared the results with ITC titrations in the absence of ligands. Herein, we observed that all the three molecules reduced the interaction between C2HRNizp1 and PHDvC5HCHNSD1 by one order of magnitude, with the dissociation constant increasing from 4 µM to 40–50 µM in the absence and presence of ligands, respectively (Fig. 8A–D, Table 2). Saturation of PHDvC5HCHNSD1 with 1–3 reduced the contributions of both the enthalpic and the entropic terms to the ΔG of binding. These results, in accordance with the observed CSPs in NMR titrations, support the notion that 1–3 target at least in part the C2HRNizp1 binding site herewith weakening the interaction between PHDvC5HCHNSD1 and C2HRNizp1.

5. Discussion and conclusions

PHD fingers are small epigenetic readers able to decode the modification status of histones [5,6]. They are involved in several diseases, especially in cancer, thus their pharmacological targeting is starting to be considered as a complementary therapeutic strategy to the classical enzymatic inhibition of their host proteins [44].
These small Zn$^{2+}$ binding domains are versatile structural platforms well suited for diversified protein–protein interactions. This is the case for the PHD fingers of MLL1 [45] of Pygo2 [46] and of Sp140 [47], interacting respectively with Cyp33, Bcl9 and Pin1, or for the second PHD finger of AIRE, that functions as a hub for multiple protein–protein interactions [16]. While inhibitors or chemical probes of the histone binding activity of PHD fingers are starting to emerge [11–13], the druggability of PHD fingers (alone or in tandem) as non-histone interaction platform remains completely unexplored. This is possibly due to the limited information on both the biological significance and the molecular details at the basis of these interactions. Hence, identification of chemical probes targeting these complexes would be extremely enlightening in terms of their structural and functional understanding, even though tackling large PPI targets with synthetic molecules still remains a considerable endeavor [24]. In the current study we have applied a computational and experimental pipeline to investigate the ligandability of PHD-V$_{C5HCHNSD1}$ as finger–finger interaction platform. To this aim we took advantage of a 3D model of PHD-V$_{C5HCHNSD1}$/C2HR$_{Nizp1}$ interaction [18] and inspected PHD-V$_{C5HCHNSD1}$ structure for possible hotspots suitable for small molecules targeting. These so-called “sticky zones” have emerged as collecting sites of most of the binding energy of inhibitors, thus opening new possibilities for the rational selection of binding molecules [48,49]. Indeed FTmap analysis [26] predicted the presence of two putative contiguous ligand binding hotspots, that partially coincided with PHD V$_{C5HCHNSD1}$ interaction surface with C2HR$_{Nizp1}$. To further explore the ligandability of PHD-V$_{C5HCHNSD1}$ we performed a structure-based in silico screening followed by NMR validation of the best hits emerging from our computational protocol. We found three structurally related molecules: the type II topoisomerase inhibitor mitoxantrone (1) used as salvage therapy for AML [50], the antimalaric drugs chloroquine (3) and its acridine analog quinacrine (2), repositioned for treatment of cancer [52]. They all were able to bind with millimolar affinity to PHD-V$_{C5HCHNSD1}$. This value is well in the range of the K$_d$s measured for first hits derived from VS campaigns aiming at the identification of PPI inhibitors. For example, a millimolar affinity has been measured by NMR for Benzimidazoles able to compete with the histone-binding pocket of the Pygo PHD Finger [12]. Similarly, an
NMR fragment based screening of the PWWP1 domain of NSD3 yielded hits with mM affinities [9]. Importantly, mapping of the interaction by NMR CSPs methods confirmed that the three molecules target the C2HRNizp1 binding pocket located at the interface between PHDV and C5HCH. This surface is in accordance with the one defined by the Glide docking poses (Supplementary Fig. S5) and with the predicted hotspot region, with 1 accommodating in the CS4 pocket, and 2 and 3 each occupying two adjacent sites, i.e. CS1, CS2 and CS3, CS4, respectively. Orthogonal ligand-based NMR experiments confirmed binding. In particular, epitope mapping via STD experiments suggested that the fused aromatic rings, that are in common to the three molecules, mostly contribute to the interaction. Most likely they create apolar interactions with the small hydrophobic patch at the interdomain interface. Intriguingly, the quinolinyl, acridyl and antraquinone moities of chloroquine (3), quinacrine (2) and mitoxantrone (1), respectively, are reminiscent of the indole moiety of the RWR motif of C2HRNizp1 and might mimic its crucial interaction with PHDV[C5HCH]NSD1. As a matter of fact, saturation of PHDV[C5HCH]NSD1 with an excess of the single ligands resulted in a reduction of the finger-finger interaction strength by one order of magnitude, as assessed by ITC measurements. We are aware of the fact that the affinities of the identified compounds are still not appropriate for in vivo applications. PPI inhibitors with in vivo efficacy typically have high nanomolar-low micromolar affinities to their targets. This applies for example for the molecules JQ1 and nutlin, inhibitors of the BET-H4acetylated [53] and of MDM-p53 interactions [54], respectively. Thus, future work should be dedicated to optimize the chemical scaffolds identified in this work in order to generate more potent inhibitors. Our results suggest that the molecules that we have identified mimic only in part the interactions that are crucial for PHDV[C2HRNizp1]NSD1/C2HRNizp1 complex formation. We hypothesize that fragment-based approaches in which the identification and linkage of fragments targeting contiguous hotspots could be a successful strategy. Alternatively, peptidomimetic approaches could be a viable strategy to target non-contiguous hotspots [48,53]. Design of peptidomimetic of C2HRNizp1 coupled to click-chemistry stabilization are currently ongoing. Nevertheless, the results obtained in this study, show for the first time that a finger-finger interaction, that involves a relatively large interaction surface composed on one side by a RWR signature and by an α-helix, and on the other side by a shallow hydrophobic groove, has proven tractable by small-molecule inhibition. The identified compounds may be thus considered as interesting leads for the development of new and more efficient NSD1/Nizp1 inhibitors. The determination of a high resolution three-dimensional structure of the PHDV[C5HCH]NSD1/C2HRNizp1 complex will be fundamental for the tailored design of ligands (peptidomimetics, small 

Fig. 5. Mapping of the ligands binding sites. A) Histograms showing chemical shift perturbations (CSPs) of 15-N-labeled PHDV[C5HCH]NSD1 amides (0.1 mM) upon addition of 20-fold excess of 1 (top), 2 (middle), 3 (bottom). Missing residues are prolines. Green circles indicate residues whose amides resonances are not present in the free protein because of exchange with the solvent. Red triangles indicate residues whose amide resonances disappear upon ligand addition (C2146NSD1, L2147NSD1, N2148NSD1, W2157NSD1, E2158NSD1 for 1 and L2147NSD1 for 2). Residues with CSPs > avg + sd elicited by 1 (top), 2 (middle), 3 (bottom) (or disappearing upon ligand binding) are projected in cyan on B) their corresponding binding pose; on C) PHDV[C5HCH]NSD1 in complex with C2HRNizp1 (cartoon representation). Residues whose resonances were perturbed upon addition of C2HRNizp1 are shown in yellow. Residues affected by both the ligands and C2HRNizp1 are highlighted in magenta. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
molecules) targeting the non-histone binding properties of these tandem PHD fingers.

6. Author statement

AB performed the experiments, analyzed the results and wrote the manuscript. MG performed the virtual screening analyzed the results and wrote the manuscript. GQ performed NMR experiments. GM, AB, MG conceived and designed throughout the studies, analyzed and interpreted all the achieved results. GM wrote the manuscript. All authors reviewed and approved the final manuscript.

CRediT authorship contribution statement

Andrea Berardi: Investigation, Formal analysis, Methodology, Validation, Visualization Data curation Writing original draft. Michela Ghitti: Investigation, Formal analysis, Methodology, Validation, Visualization Data curation. Giacomo Quilici: Investigation, Methodology. Giovanna Musco: Conceptualization, Supervision, Writing original draft, review and editing, funding acquisition.

Acknowledgements

Not applicable.

Funding

This work was supported by Italian Ministry of Health (RF-RF-2013-02354880) and by the Italian Association for Cancer Research (AIRC) (IG-21440).

Competing interests

Declarations of interest: none.
Fig. 7. Binding pose of 1–3. A) Ligand Interaction diagram and B) binding pose of 1 (left), 2 (center) and 3 (right). Molecules and protein interacting residues are shown in orange and blue sticks, respectively. Hydrogen bond, salt bridge, π-stacking and hydrophobic interactions are shown with blue line, yellow, green and grey dot lines, respectively. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Fig. 8. Molecules 1–3 reduce the interaction between C2HRNizp1 and PHDVC5HCHNSD1. ITC-binding curves of C2HRNizp1 to PHDVC5HCHNSD1, in the presence of twenty-fold excess of A) 1, B) 2, C) 3 and D) in the absence [18] of 1–3. The upper panel shows the sequential heat pulses for domain-domain binding, and the lower panel shows the integrated data, corrected for heat of dilution and fit to a single-site-binding model using a nonlinear least-squares method (line). The dissociation constants are indicated.
[44] Dawson MA, Kozarides T, Huntly BJP. Targeting epigenetic readers in cancer. N Engl J Med 2012;367:647–57. https://doi.org/10.1056/NEJMra1112635.

[45] Wang Z, Song J, Milne TA, Wang GG, Li H, Allis CD, et al. Pro isomerization in MLL1 PHD1-bromo cassette connects H3K4me readout to CyP33 and HDAC-mediated repression. Cell 2010;141:1183–94. https://doi.org/10.1016/j.cell.2010.05.016.

[46] Fiedler M, Sanchez-Barrena MJ, Nekrasov M, Mieszczanek J, Rybin V, Mueller J, et al. Decoding of methylated histone H3 tail by the Pygo-BCL9 Wnt signaling complex. Mol Cell 2008;30:507–18. https://doi.org/10.1016/j.molcel.2008.03.011.

[47] Zucchelli C, Tamburri S, Quilici G, Palagano E, Berardi A, Saare M, et al. Structure of human Sp140 PHD finger: an atypical fold interacting with Pin1. FEBS J 2014;281:216–31. https://doi.org/10.1111/febs.12758.

[48] London N, Raveh B, Schueler-Furman O. Druggable protein–protein interactions – from hot spots to hot segments. Curr Opin Chem Biol 2013;17:952–9. https://doi.org/10.1016/j.cbpa.2013.10.011.

[49] Bakail M, Ochsenbein F. Targeting protein–protein interactions, a wide open field for drug design. C R Chim 2016;19:19–27. https://doi.org/10.1016/j.crci.2015.12.004.

[50] Economides MP, McCue D, Boruthakur G, Pemmaraju N. Topoisomerase II inhibitors in AML: past, present, and future. Expert Opin Pharmacother 2019;20:1637–44. https://doi.org/10.1080/14656566.2019.1621297.

[51] Plantone D, Koudriaevtseva T. Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review. Clin Drug Invest 2018;38:653–71. https://doi.org/10.1007/s40261-018-0656-v.

[52] Gurova K. New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents. Futur Oncol 2009;5:1685–704. https://doi.org/10.2217/fon.09.127.

[53] Cunningham AD, Qvit N, Mochly-Rosen D. Peptides and peptidomimetics as regulators of protein–protein interactions. Curr Opin Struct Biol 2017;44:59–66. https://doi.org/10.1016/j.sbi.2016.12.009.